ACROSS
6. FDA approved systemic therapy for BCG unresponsive CIS
8. Current standard of care for metastatic papillary RCC
9. Drug shown to improve DFS in adjuvant settings in patients with RCC at high risk for recurrence
10. FDA approved tyrosine kinase inhibitor for metastatic urothelial cancer post platinum chemotherapy
DOWN
3. FDA approved antibody-drug conjugate for locally advanced or metastatic urothelial cancer
4. HIF-2α inhibitor approved by FDA for VHL associated RCC & other tumors
1. FDA approved for mCRPC with deleterious BRCA mutations
7. Monoclonal antibody against carbonic anhydrase IX
2. Oral GnRH antagonist
5. FDA approved for adjuvant treatment in urothelial cancer who are platinum ineligible